<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VASOSTRICT- vasopressin, unspecified injection </strong><br>Par Pharmaceutical, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VASOSTRICT™ safely and effectively. See full prescribing information for VASOSTRICT.<br><br>Vasostrict (vasopressin injection) for intravenous use<br>Initial U.S. Approval: 2014</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul><li>Vasostrict is indicated to increase blood pressure in adults with vasodilatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> (e.g., post-cardiotomy or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>) who remain hypotensive despite fluids and catecholamines. (<a href="#S1">1</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Dilute Vasostrict with normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) to either 0.1 units/mL or 1 unit/mL for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration. (<a href="#S2.1">2.1</a>)</li>
<li>Post-cardiotomy <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>: 0.03 to 0.1 units/minute (<a href="#S2.2">2.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">Septic shock</span>: 0.01 to 0.07 units/minute (<a href="#S2.2">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Injection:  20 units per mL; packaged as 1 mL per vial (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>Vasostrict is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to 8-L-arginine vasopressin or chlorobutanol. (<a href="#S4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul><li>Can worsen cardiac function. (<a href="#S5.1">5.1</a>)</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions include decreased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> (coronary, mesenteric, skin, digital). (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical, Inc. at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Pressor effects of catecholamines and Vasostrict are expected to be additive. (<a href="#S7.1">7.1</a>)</li>
<li>Indomethacin may prolong effects of Vasostrict. (<a href="#S7.2">7.2</a>)</li>
<li>Co-administration of ganglionic blockers or drugs causing <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span> may increase the pressor response. (<a href="#S7.3">7.3</a>, <a href="#S7.5">7.5</a>)</li>
<li>Co-administration of drugs causing <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span> may decrease the pressor  response. (<a href="#S7.6">7.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>
<span class="Bold">Pregnancy: </span>May induce uterine contractions. (<a href="#S8.1">8.1</a>)</li>
<li>
<span class="Bold">Pediatric Use: </span>Safety and effectiveness have not been established. (<a href="#S8.4">8.4</a>)</li>
<li>
<span class="Bold">Geriatric Use: </span>No safety issues have been identified in older patients. (<a href="#S8.5">8.5</a>)</li>
</ul></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsRevision">Revised: 5/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1       Preparation of Diluted Solutions</a></h2>
<h2><a href="#section-2.2" class="toc">2.2       Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1       Worsening Cardiac Function</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1       Catecholamines</a></h2>
<h2><a href="#section-7.2" class="toc">7.2       Indomethacin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3       Ganglionic Blocking Agents</a></h2>
<h2><a href="#section-7.4" class="toc">7.4       Furosemide</a></h2>
<h2><a href="#section-7.5" class="toc">7.5       Drugs Suspected of Causing <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span></a></h2>
<h2><a href="#section-7.6" class="toc">7.6       Drugs Suspected of Causing <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13        NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Vasostrict™ is indicated to increase blood pressure in adults with vasodilatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> (e.g., post-cardiotomy or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>) who remain hypotensive despite fluids and catecholamines.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1       Preparation of Diluted Solutions</h2>
<p class="First">Dilute Vasostrict in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use.  Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.</p>
<table width="75%">
<caption><span>Table 1 Preparation of diluted solutions</span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="center" rowspan="2">Fluid restriction?</th>
<th class="Rrule" align="center" rowspan="2">Final concentration</th>
<th class="Botrule Rrule" align="center" colspan="2">Mix</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Vasostrict</th>
<th class="Rrule" align="center">Diluent</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">No</td>
<td class="Rrule" align="center">0.1 units/mL</td>
<td class="Rrule" align="center">2.5 mL (50 units)</td>
<td class="Rrule" align="center">500 mL</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Yes</td>
<td class="Rrule" align="center">1 unit/mL</td>
<td class="Rrule" align="center">5 mL (100 units)</td>
<td class="Rrule" align="center">100 mL</td>
</tr>
</tbody>
</table>
<p>Inspect parenteral drug products for particulate matter and discoloration prior to use, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2       Administration</h2>
<p class="First">The goal of treatment is optimization of perfusion to critical organs, but aggressive treatment can compromise perfusion of organs, like the gastrointestinal tract, whose function is difficult to monitor. The following advice is empirical. In general, titrate to the lowest dose compatible with a clinically acceptable response.</p>
<p>For post-cardiotomy <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, start with a dose of 0.03 units/minute.  For <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, start with a dose of 0.01 units/minute.  If the target blood pressure response is not achieved, titrate up by 0.005 units/minute at 10- to 15-minute intervals. The maximum dose for post-cardiotomy <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> is 0.1 units/minute and for <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span> 0.07 units/minute. After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper Vasostrict by 0.005 units/minute every hour as tolerated to maintain target blood pressure.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Injection:  20 units per mL; packaged as 1 mL per vial</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Vasostrict is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to 8-L-arginine vasopressin or chlorobutanol.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1       Worsening Cardiac Function</h2>
<p class="First">Use in patients with impaired cardiac response may worsen <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions associated with the use of vasopressin were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>/lymphatic system disorders: <span class="product-label-link" type="condition" conceptid="4148882" conceptname="Hemorrhagic shock">Hemorrhagic shock</span>, decreased platelets, intractable <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>: <span class="product-label-link" type="condition" conceptid="4134890" conceptname="Right heart failure">Right heart failure</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: <span class="product-label-link" type="condition" conceptid="192673" conceptname="Vascular insufficiency of intestine">Mesenteric ischemia</span></p>
<p>Hepatobiliary: Increased bilirubin levels</p>
<p>Renal/urinary disorders: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal insufficiency</span></p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>: Distal limb <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> </p>
<p>Metabolic: <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></p>
<p>Skin: Ischemic lesions</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1       Catecholamines</h2>
<p class="First">Use with <span class="Italics">catecholamines</span> is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2       Indomethacin</h2>
<p class="First">Use with <span class="Italics">indomethacin</span> may prolong the effect of Vasostrict on <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> and systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3       Ganglionic Blocking Agents</h2>
<p class="First">Use with <span class="Italics">ganglionic blocking agents</span> may increase the effect of Vasostrict on mean arterial blood pressure <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4       Furosemide</h2>
<p class="First">Use with <span class="Italics">furosemide</span> increases the effect of Vasostrict on osmolar clearance and urine flow <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5       Drugs Suspected of Causing <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span></h2>
<p class="First">Use with <span class="Italics">drugs suspected of causing <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span></span> (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6       Drugs Suspected of Causing <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">Diabetes Insipidus</span></h2>
<p class="First">Use with <span class="Italics">drugs suspected of causing <span class="product-label-link" type="condition" conceptid="30968" conceptname="Diabetes insipidus">diabetes insipidus</span></span> (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasostrict.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary: </span>There are no adequate or well-controlled studies of Vasostrict in pregnant women.  It is not known whether vasopressin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Animal reproduction studies have not been conducted with vasopressin <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Clinical Considerations: </span>Because of increased clearance of vasopressin in the second and third trimester, the dose of Vasostrict may need to be up-titrated to doses exceeding 0.1 units/minute in post-cardiotomy <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and 0.07 units/minute in <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>. </p>
<p>Vasostrict may produce tonic uterine contractions that could threaten the continuation of pregnancy<span class="Italics">.</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether vasopressin is present in human milk.  However, oral absorption by a nursing infant is unlikely because vasopressin is rapidly destroyed in the gastrointestinal tract. Consider advising a lactating woman to pump and discard breast milk for 1.5 hours after receiving vasopressin to minimize potential exposure to the breastfed infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of Vasostrict in pediatric patients with vasodilatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <span class="Italics">[see <a href="#S5">Warnings and Precautions (5)</a>, <a href="#S6">Adverse Reactions (6)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage with Vasostrict can be expected to manifest as consequences of <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> of various vascular beds (peripheral, mesenteric, and coronary) and as <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. In addition, overdosage may lead less commonly to <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachyarrhythmias</span> (including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>), <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and non-specific <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>.</p>
<p>Direct effects will resolve within minutes of withdrawal of treatment.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Vasopressin is a polypeptide hormone that causes contraction of vascular and other smooth muscles and antidiuresis. Vasostrict is a sterile, aqueous solution of synthetic arginine vasopressin for intravenous administration. The 1 mL solution contains vasopressin 20 units/mL, chlorobutanol, NF 0.5% as a preservative, and Water for Injection, USP adjusted with acetic acid to pH 3.4 – 3.6.</p>
<p>The chemical name of vasopressin is Cyclo (1-6) L-Cysteinyl-L-Tyrosyl-L-Phenylalanyl-L-Glutaminyl-L-Asparaginyl-L-Cysteinyl-L-Prolyl-L-Arginyl-L-Glycinamide. It is a white to off-white amorphous powder, freely soluble in water. The structural formula is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b1147beb-743e-4c62-8927-91192447f8b8&amp;name=vasostrict-01.jpg"></p>
<p>Molecular Formula: C<span class="Sub">46</span>H<span class="Sub">65</span>N<span class="Sub">15</span>O<span class="Sub">12</span>S<span class="Sub">2 </span>                Molecular Weight: 1084.23</p>
<p>One mg is equivalent to 530 units.   </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">The vasoconstrictive effects of vasopressin are mediated by vascular V<span class="Sub">1</span> receptors. Vascular V<span class="Sub">1</span> receptors are directly coupled to phopholipase C, resulting in release of calcium, leading to <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>.  In addition, vasopressin stimulates antidiuresis via stimulation of V<span class="Sub">2</span> receptors which are coupled to adenyl cyclase.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">At therapeutic doses exogenous vasopressin elicits a vasoconstrictive effect in most vascular beds including the splanchnic, renal and cutaneous circulation. In addition, vasopressin at pressor doses triggers contractions of smooth muscles in the gastrointestinal tract mediated by muscular V<span class="Sub">1</span>-receptors and release of prolactin and ACTH via V<span class="Sub">3</span> receptors. At lower concentrations typical for the antidiuretic hormone vasopressin inhibits water <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> via renal V<span class="Sub">2</span> receptors.</p>
<p>In patients with vasodilatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> vasopressin in therapeutic doses increases systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and mean arterial blood pressure and reduces the dose requirements for norepinephrine. Vasopressin tends to decrease heart rate and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>. The pressor effect is proportional to the infusion rate of exogenous vasopressin. Onset of the pressor effect of vasopressin is rapid, and the peak effect occurs within 15 minutes. After stopping the infusion the pressor effect fades within 20 minutes. There is no evidence for <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span> or tolerance to the pressor effect of vasopressin in patients.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">At infusion rates used in vasodilatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> (0.01-0.1 units/minute) the clearance of vasopressin is 9 to 25 mL/min/kg in patients with vasodilatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. The apparent t<span class="Sub">1/2</span> of vasopressin at these levels is ≤10 minutes. Vasopressin is predominantly metabolized and only about 6% of the dose is excreted unchanged in urine. Animal experiments suggest that the metabolism of vasopressin is primarily by liver and kidney. Serine protease, carboxipeptidase and disulfide oxido-reductase cleave vasopressin at sites relevant for the pharmacological activity of the hormone. Thus, the generated metabolites are not expected to retain important pharmacological activity.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Drug-Drug Interactions</span></p>
<p>Indomethacin more than doubles the time to offset for vasopressin's effect on peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> in healthy subjects <span class="Italics">[see <a href="#S7.2">Drug Interactions (7.2)</a>]</span></p>
<p>The ganglionic blocking agent tetra-ethylammonium increases the pressor effect of vasopressin by 20% in healthy subjects <span class="Italics">[see <a href="#S7.3">Drug Interactions (7.3)</a>].</span></p>
<p>Furosemide increases osmolar clearance 4-fold and urine flow 9-fold when co-administered with exogenous vasopressin in healthy subjects <span class="Italics">[see <a href="#S7.4">Drug Interactions (7.4)</a>].</span></p>
<p>Halothane, morphine, fentanyl, alfentanyl and sufentanyl do not impact exposure to endogenous vasopressin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy: </span>Because of a spillover into blood of placental vasopressinase the clearance of exogenous and endogenous vasopressin increases gradually over the course of a pregnancy. During the first trimester of pregnancy the clearance is only slightly increased. However, by the third trimester the clearance of vasopressin is increased about 4-fold and at term up to 5-fold. After delivery the clearance of vasopressin returns to pre-conception baseline within two weeks<span class="Italics">.</span></p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13        NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No formal carcinogenicity or fertility studies with vasopressin have been conducted in animals. Vasopressin was found to be negative in the <span class="Italics">in vitro</span> bacterial mutagenicity (Ames) test and the <span class="Italics">in vitro </span>Chinese hamster ovary (CHO) cell chromosome aberration test. In mice, vasopressin has been reported to have an effect on function and fertilizing ability of spermatozoa.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Increases in systolic and mean blood pressure following administration of vasopressin were observed in 7 studies in <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span> and 8 in post-cardiotomy vasodilatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Vasostrict (vasopressin injection, USP) is supplied in vials as follows:</p>
<p>A carton of 25 multi-dose vials each containing vasopressin 1 mL at 20 units/mL.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">									Store between 2°C and 8°C (36°F and 46°F).  Do not freeze.			</p>
<p>Discard vial after 48 hours after first puncture.</p>
<p>NDC 42023-164-25 (carton)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">Manufactured by:<br><span class="Bold">Par Pharmaceutical Companies, Inc.</span><br>Spring Valley, NY 10977</p>
<p>I05/14<br>OS164J-01-90-01</p>
<p>Vasostrict is a registered trademark of Par Pharmaceutical Companies, Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 25 Vial Carton</h1>
<p class="First">NDC 42023-<span class="Bold">164</span>-25<br>Rx Only</p>
<p><span class="Bold">Vasostrict</span>™<br><span class="Bold">(Vasopressin Injection, USP)</span></p>
<p><span class="Bold">20 Units per mL</span></p>
<p><span class="Bold">For Intravenous Infusion<br>Must be diluted prior to use <br> Store between 2°C and 8°C (36°F and 46°F).</span></p>
<p>1 mL x 25 Multiple Dose Vials</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 25 Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b1147beb-743e-4c62-8927-91192447f8b8&amp;name=vasostrict-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VASOSTRICT 		
					</strong><br><span class="contentTableReg">vasopressin injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:42023-164</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Vasopressin, Unspecified</strong> (Vasopressin, Unspecified) </td>
<td class="formItem">Vasopressin, Unspecified</td>
<td class="formItem">20 [USP'U]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Chlorobutanol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Acetic acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42023-164-25</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:42023-164-01</td>
<td class="formItem">1 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204485</td>
<td class="formItem">11/12/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Par Pharmaceutical, Inc.
							(092733690)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e1bc7c2b-a536-49a4-97e4-dfac673f393b</div>
<div>Set id: b1147beb-743e-4c62-8927-91192447f8b8</div>
<div>Version: 4</div>
<div>Effective Time: 20141106</div>
</div>
</div> <div class="DistributorName">Par Pharmaceutical, Inc.</div></p>
</body></html>
